|
1
|
Mellin H, Friesland S, Lewensohn R,
Dalianis T and Munck-Wikland E: Human papillomavirus (HPV) DNA in
tonsillar cancer: Clinical correlates, risk of relapse, and
survival. Int J Cancer. 89:300–304. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dahlgren L, Dahlstrand HM, Lindquist D,
Högmo A, Björnestål L, Lindholm J, Lundberg B, Dalianis T and
Munck-Wikland E: Human papillomavirus is more common in base of
tongue than in mobile tongue cancer and is a favorable prognostic
factor in base of tongue cancer patients. Int J Cancer.
112:1015–1019. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Attner P, Du J, Näsman A, Hammarstedt L,
Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E:
Human papillomavirus and survival in patients with base of tongue
cancer. Int J Cancer. 128:2892–2897. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sivars L, Näsman A, Tertipis N, Vlastos A,
Ramqvist T, Dalianis T, Munck-Wikland E and Nordemar S: Human
papillomavirus and p53 expression in cancer of unknown primary in
the head and neck region in relation to clinical outcome. Cancer
Med. 3:376–384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dalianis T: Human papillomavirus and
oropharyngeal cancer, the epidemics, and significance of additional
clinical biomarkers for prediction of response to therapy (review).
Int J Oncol. 44:1799–1805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marklund L, Näsman A, Ramqvist T, Dalianis
T, Munck-Wikland E and Hammarstedt L: Prevalence of human
papillomavirus and survival in oropharyngeal cancer other than
tonsil or base of tongue cancer. Cancer Med. 1:82–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robinson KL and Macfarlane GJ:
Oropharyngeal cancer incidence and mortality in scotland: Are rates
still increasing? Oral Oncol. 39:31–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hammarstedt L, Lindquist D, Dahlstrand H,
Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W,
Dalianis T and Munck-Wikland E: Human papillomavirus as a risk
factor for the increase in incidence of tonsillar cancer. Int J
Cancer. 119:2620–2623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sturgis EM and Cinciripini PM: Trends in
head and neck cancer incidence in relation to smoking prevalence:
An emerging epidemic of human papillomavirus-associated cancers?
Cancer. 110:1429–1435. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Näsman A, Attner P, Hammarstedt L, Du J,
Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M,
Lindquist D, et al: Incidence of human papillomavirus (HPV)
positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of
viral-induced carcinoma? Int J Cancer. 125:362–366. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braakhuis BJ, Visser O and Leemans CR:
Oral and oropharyngeal cancer in the Netherlands between 1989 and
2006: Increasing incidence, but not in young adults. Oral Oncol.
45:e85–89. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Attner P, Du J, Näsman A, Hammarstedt L,
Ramqvist T, Lindholm J, Marklund L, Dalianis T and Munck-Wikland E:
The role of human papillomavirus in the increased incidence of base
of tongue cancer. Int J Cancer. 126:2879–2884. 2010.PubMed/NCBI
|
|
13
|
Chaturvedi AK, Engels EA, Pfeiffer RM,
Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M,
Cozen W, et al: Human papillomavirus and rising oropharyngeal
cancer incidence in the United States. J Clin Oncol. 29:4294–4301.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Näsman A, Nordfors C, Holzhauser S,
Vlastos A, Tertipis N, Hammar U, Hammarstedt-Nordenvall L, Marklund
L, Munck-Wikland E, Ramqvist T, et al: Incidence of human
papillomavirus positive tonsillar and base of tongue carcinoma: A
stabilisation of an epidemic of viral induced carcinoma? Eur J
Cancer. 51:55–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haeggblom L, Attoff T, Yu J, Holzhauser S,
Vlastos A, Mirzae L, Ährlund-Richter A, Munck-Wikland E, Marklund
L, Hammarstedt-Nordenvall L, et al: Changes in incidence and
prevalence of human papillomavirus in tonsillar and base of tongue
cancer during 2000–2016 in the Stockholm region and Sweden. Head
Neck. 41:1583–1590. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mirghani H, Amen F, Blanchard P, Moreau F,
Guigay J, Hartl DM and Lacau St Guily J: Treatment de-escalation in
HPV-positive oropharyngeal carcinoma: Ongoing trials, critical
issues and perspectives. Int J Cancer. 136:1494–1503. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Näsman A, Bersani C, Lindquist D, Du J,
Ramqvist T and Dalianis T: Human papillomavirus and potentially
relevant biomarkers in tonsillar and base of tongue squamous cell
carcinoma. Anticancer Res. 37:5319–5328. 2017.PubMed/NCBI
|
|
18
|
Bersani C, Mints M, Tertipis N, Haeggblom
L, Sivars L, Ährlund-Richter A, Vlastos A, Smedberg C, Grün N,
Munck-Wikland E, et al: A model using concomitant markers for
predicting outcome in human papillomavirus positive oropharyngeal
cancer. Oral Oncol. 68:53–59. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Näsman A, Andersson E, Marklund L,
Tertipis N, Hammarstedt-Nordenvall L, Attner P, Nyberg T, Masucci
GV, Munck-Wikland E, Ramqvist T and Dalianis T: HLA class I and II
expression in oropharyngeal squamous cell carcinoma in relation to
tumor HPV status and clinical outcome. PLoS One. 8:e770252013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Näsman A, Nordfors C, Grün N,
Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D and Dalianis
T: Absent/weak CD44 intensity and positive human papillomavirus
(HPV) status in oropharyngeal squamous cell carcinoma indicates a
very high survival. Cancer Med. 2:507–518. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tertipis N, Haeggblom L, Nordfors C, Grün
N, Näsman A, Vlastos A, Dalianis T and Ramqvist T: Correlation of
LMP10 expression and clinical outcome in human papillomavirus (HPV)
positive and HPV-negative tonsillar and base of tongue cancer. PLoS
One. 9:e956242014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lindquist D, Näsman A, Tarján M,
Henriksson R, Tot T, Dalianis T and Hedman H: Expression of LRIG1
is associated with good prognosis and human papillomavirus status
in oropharyngeal cancer. Br J Cancer. 110:1793–1800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tertipis N, Villabona L, Nordfors C,
Näsman A, Ramqvist T, Vlastos A, Masucci G and Dalianis T: HLA-A*02
in relation to outcome in human papillomavirus positive tonsillar
and base of tongue cancer. Anticancer Res. 34:2369–2375.
2014.PubMed/NCBI
|
|
25
|
Nordfors C, Grün N, Tertipis N,
Ährlund-Richter A, Haeggblom L, Sivars L, Du J, Nyberg T, Marklund
L, Munck-Wikland E, et al: CD8+ and CD4+
tumour infiltrating lymphocytes in relation to human papillomavirus
status and clinical outcome in tonsillar and base of tongue
squamous cell carcinoma. Eur J Cancer. 49:2522–2530. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ramqvist T, Mints M, Tertipis N, Näsman A,
Romanitan M and Dalianis T: Studies on human papillomavirus (HPV)
16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue
cancer in relation to clinical outcome and immunological
parameters. Oral Oncol. 51:1126–1131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rietbergen MM, Martens-de Kemp SR,
Bloemena E, Witte BI, Brink A, Baatenburg de Jong RJ, Leemans CR,
Braakhuis BJ and Brakenhoff RH: Cancer stem cell enrichment marker
CD98: A prognostic factor for survival in patients with human
papillomavirus-positive oropharyngeal cancer. Eur J Cancer.
50:765–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tinhofer I, Budach V, Saki M, Konschak R,
Niehr F, Jöhrens K, Weichert W, Linge A, Lohaus F, Krause M, et al:
Targeted next-generation sequencing of locally advanced squamous
cell carcinomas of the head and neck reveals druggable targets for
improving adjuvant chemoradiation. Eur J Cancer. 57:78–86. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bersani C, Sivars L, Haeggblom L,
DiLorenzo S, Mints M, Ährlund-Richter A, Tertipis N, Munck-Wikland
E, Näsman A, Ramqvist T and Dalianis T: Targeted sequencing of
tonsillar and base of tongue cancer and human papillomavirus
positive unknown primary of the head and neck reveals prognostic
effects of mutated FGFR3. Oncotarget. 8:35339–35350. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bersani C, Haeggblom L, Ursu RG, Giusca
SE, Marklund L, Ramqvist T, Näsman A and Dalianis T: Overexpression
of FGFR3 in HPV-positive tonsillar and base of tongue cancer is
correlated to outcome. Anticancer Res. 38:4683–4690. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koole K, van Kempen PM, Swartz JE, Peeters
T, van Diest PJ, Koole R, van Es RJ and Willems SM: Fibroblast
growth factor receptor 3 protein is overexpressed in oral and
oropharyngeal squamous cell carcinoma. Cancer Med. 5:275–284. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghedini GC, Ronca R, Presta N and
Giacomini A: Future applications of FGF/FGFR inhibitors in cancer.
Expert Rev of Anticancer Ther. 18:861–872. 2018. View Article : Google Scholar
|
|
33
|
Arafeh R and Samuels Y: PIK3CA in cancer:
The past 30 years. Semin Cancer Biol. 2019.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brenner JC, Graham MP, Kumar B, Saunders
LM, Kupfer R, Lyons RH, Bradford CR and Care TE: Genotyping of 73
USCC head and neck squamous cell carcinoma cell lines. Head Neck.
32:417–426. 2010.PubMed/NCBI
|
|
35
|
White JS, Weissfeld JL, Ragin CCR, Rossie
KM, Martin CL, Shuster M, Ishwad CS, Law JC, Myers EN, Johnson JT
and Gollin SM: The influence of clinical and demographic risk
factors on the establishment of head and neck squamous cell
carcinoma cell lines. Oral Oncol. 43:701–712. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lange MJ, Lasiter JC and Misfeldt ML:
Toll-like receptros in tonsillar epithelial cells. Int J Pediatr
Otorhinolaryngol. 73:613–621. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang L, Šuštić T, Leite de Oliveira R,
Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den
Heuvel MM, Bernards R and van der Heijden MS: A functional genetic
screen identifies the phosphinositide 3-kinas pathway as a
determinant of resistance to fibroblast grown factor receptor
inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol.
71:858–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Mikse O, Liao RG, Li Y, Tan L,
Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated
ERBB2/3 activation confers acquired resistance to FGFR inhibition
in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herrera-Abreu MT, Pearson A, Campbell J,
Shnyder SD, Knowles MA, Ashworth A and Turner NC: Parallel RNA
interference screens identify EGFR activation as an escape
mechanism in FGFR3-mutant cancer. Cancer Discov. 3:1058–1071. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brands RC, Knierim LM, De Donno F,
Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter
UDA: Targeting VEGFR and FGFR in head and neck squamous cell
carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma BB, Lui VW, Hui CW, Lau CP, Wong CH,
Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, et al: Preclinical
evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal
models. Cancer Lett. 343:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koole K, Brunen D, van Kempen PM, Noorlag
R, de Bree R, Lieftink C, van Es RJ, Bernards R and Willems SM:
FGFR1 is a potential prognostic biomarker and therapeutic target in
head and neck squamous cell carcinoma. Clin Cancer Res.
22:3884–3893. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Singleton KR, Hinz TK, Kleczko EK, Marek
LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi
screens reveal synergistic targeting of MTOR and FGFR1 pathways for
treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Munster P, Aggarwal R, Hong D, Schellens
JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC,
Bergsland E, et al: First-in-human phase I study of GSK2126458, an
oral pan-class I phosphatidylinositol-3-kinase inhibitor, in
patients with advanced solid tumor malignancies. Clin Cancer Res.
22:1932–1939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tamura R, Yoshihara K, Saito T, Ishimura
R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda
K, et al: Novel therapeutic strategy for cervical cancer harboring
FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Esposito A, Viale G and Curigliano G:
Safety, tolerability, and management of toxic effects of
phosphatidylinositol 3-kinase inhibitor treatment in patients with
cancer: A review. JAMA Oncol. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schram AM, Voss MH and Hyman DM:
Genome-driven paradigm for the development of selective fibroblast
growth factor receptor inhibitors. J Clin Oncol. 35:131–134. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
de Weerdt I, Koopmans SM, Kater AP and van
Gelder M: Incidence and management of toxicity associated with
ibrutinib and idelalisib: A practical approach. Haematologica.
102:1629–1639. 2017. View Article : Google Scholar : PubMed/NCBI
|
